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Sarcoidosis or sarcoid reactions, which appear as FDG-avid lesions in oncologic patients, need to be differentiated
from disseminated malignancies. We aimed to promote awareness of development of sarcoidosis or sarcoid
reactions after antineoplastic therapy to avoid diagnostic errors with FDG-PET/CT findings and assess the utility of
FDG-PET/CT for follow-up. We retrospectively reviewed radiological reports of FDG-PET/CT scans performed
between January 2009 and December 2011. Among oncologic patients with more than 2 FDG-PET/CT scans, those
with nearly symmetrical increases in FDG uptake in the hilar or mediastinal lymph nodes were identified, and those
with known sarcoidosis, concurrent diagnoses of sarcoidosis with malignancy, or histopathologically proven
malignancies were excluded. Then, only those cases were selected for which sarcoidosis or sarcoid reactions were
diagnosed. Four of 376 oncologic cases met the criteria. At 9 months to 6 years after antineoplastic therapy,
abnormal FDG uptakes were observed in the hilar, mediastinal, abdominal, pelvic, and inguinal nodes, and/or
spleen and lung parenchyma with SUVmax up to 17.7. On the basis of these findings, 1 patient received anticancer
chemotherapy because of tumor recurrence suspicion. A gradual decrease in FDG uptake was observed on
subsequent PET/CT scans. Sarcoidosis or sarcoid reactions should be considered in differential diagnosis of
oncologic patients who have developed FDG-avid lesions any time after antineoplastic therapy. FDG-PET/CT can be
used for follow-up in nondiagnostic situations to detect decreases in FDG uptake due to presence of sarcoidal
granulomas.
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Sarcoidosis is a multisystem granulomatous disease of
unknown origin that is characterized by the presence of
noncaseating granulomas in affected tissues. Sarcoidal
granulomas can involve any organ, but in most cases,
intrathoracic lymph-node swelling, pulmonary involve-
ment, and ocular or skin involvement are observed
(Iannuzzi et al., 2007). Although the relationship be-
tween sarcoidosis and malignancies is controversial,
hematological malignancies and solid tumors develop in
sarcoidosis patients and sarcoidosis develops in onco-
logic patients (Cohen and Kurzrock,2007; Pavic et al.,
2008). In oncologic patients, sarcoid reactions (or
sarcoid-like reactions), which refer to the development
of noncaseating granulomas in patients who do not* Correspondence: kenta@idac.tohoku.ac.jp
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in any medium, provided the original work is pfulfill the criteria for systemic sarcoidosis, have been
observed. Sarcoid reactions occur most commonly in
the lymph nodes draining a malignant tumor, but they
have also been observed in the stroma, the organ of
tumor origin, and distant tissues (Brincker, 1986). The
development of sarcoidosis or sarcoid reactions in on-
cologic patients has been observed after antineoplastic
treatment with biologic modifiers such as interferon
and interleukin-2, with single or combinations of
chemotherapy agents (Cohen and Kurzrock, 2007; Pavic
et al., 2008), or even after surgery without chemother-
apy (Kennedy et al., 2008).
Positron emission tomography (PET) and PET/com-
puted tomography (CT) with 2-deoxy-2-[F-18]fluoro-D-
glucose (FDG) have been widely used in the management
of malignancy based on the increased use of glucose by
malignant cells. The use of FDG-PET/CT for staging,
assessing the response to therapy, and diagnosing the re-
currence of malignancy is, however, hampered by activeOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Inoue et al. SpringerPlus 2013, 2:113 Page 2 of 7
http://www.springerplus.com/content/2/1/113inflammation and granulation tissues, which are also
known to accumulate FDG (Shreve et al., 1999). Active
sarcoidosis shows high FDG uptake and, therefore, can be
a pitfall for the diagnosis of malignancies in one respect,
but repeated FDG-PET can be used for the assessment of
the activity of sarcoidosis and its response to therapy
(Teirstein et al., 2007; Braun et al., 2008).
With the increasing use of FDG-PET/CT, a number of
studies have described that the development of sarcoid-
osis or sarcoid reactions results in FDG uptake that
needs to be differentiated from disseminated malignan-
cies in patients with a history of treatment for malignan-
cies, within a few months to more than 10 years after
the diagnosis of the malignancy (Chowdhury et al., 2009;
Hunt et al., 2009).
We aimed to promote awareness about the develop-
ment of sarcoidosis or sarcoid reactions after antineo-
plastic therapy in order to avoid diagnostic errors with
FDG-PET/CT findings and assess the utility of FDG-
PET/CT for follow-up in this situation. Therefore, we
describe FDG-PET/CT findings and the time course
around the detection of FDG-avid lesions in patients
with sarcoidosis or sarcoid reactions that developed after
antineoplastic therapy.
Materials and methods
We retrospectively reviewed the radiological reports of
PET/CT scans that were performed at our university
hospital between January 2009 and December 2011.
Among the patients who underwent oncologic FDG
PET/CT scans, those who had undergone more than 2
FDG PET/CT scans were selected. Patients with known
sarcoidosis, a concurrent diagnosis of sarcoidosis, or a
histologically proven recurrence of a malignancy, were
excluded. Patients who were referred from other hospi-
tals to our department only for PET/CT scans were also
excluded due to lack of other clinical data. By analyzing
radiological reports, patients with abnormal increases in
FDG uptake in the hilar and/or mediastinal lymph nodes
during a series of PET/CT scans were identified as cases
of suspected sarcoidosis that developed or flared after
antineoplastic therapy. Then, further information was
obtained from the clinical and pathological data, and pa-
tients diagnosed with sarcoidosis or sarcoid reactions
were selected. Imaging and clinical data from before
2009 were obtained for those patients if available. In-
formed consent was waived for this retrospective study.
The protocols of this study were approved by the Ethical
Committee of the Tohoku University Graduate School
of Medicine.
All integrated PET/CT images were obtained at our
institution with a Biograph Duo or a Biograph 40 PET/
CT system (Siemens AG, Erlangen, Germany) using our
standard clinical protocol. The patients fasted for at least4 h. An intravenous injection of 185–370 MBq (5-
10 mCi) of FDG was administered. Then, the patients
rested in a reclining chair in a quiet room for 1 h
between the tracer injection and the start of PET/CT
image acquisition. No oral or intravenous contrast
agent was used. FDG-PET emission data were typically
obtained for 2 min in each bed position during the
emission scan. Patients were instructed to continue
shallow breathing during PET acquisition. FDG-PET
images were reconstructed using the CT transmission
map for attenuation correction. FDG-PET/CT images
were interpreted in standard clinical fashion by 2
nuclear radiologists.Results
Of the 376 oncologic patients who underwent more than
2 FDG-PET/CT scans during follow-up after antineo-
plastic therapy, 4 patients were diagnosed with sarcoid-
osis or sarcoid reactions based on histopathological and
clinical data. There were several patients in whom sar-
coidosis or sarcoid reactions could be suspected based
on the PET/CT findings, but the diagnosis was not con-
firmed clinically or histopathologically. These uncon-
firmed cases were not included in this study because the
aim of this study was not to indicate the prevalence of
sarcoidosis or sarcoid reactions in patients who under-
went oncologic FDG-PET/CT scans after antineoplastic
treatment. The primary malignancy was carcinoma in 3
patients and osteosarcoma in 1 patient. The detailed
clinical histories of the patients are described as follows.Case 1
A 43-year-old man was treated for nonseminomatous
malignant germ cell tumors with multiple intrathoracic
and abdominal lymph nodes and lung metastases
(Figure 1a) by chemotherapy (1 cycle of the combin-
ation of etoposide and cisplatin, 2 cycles of the combin-
ation of bleomicyn, etoposide and cisplatin, and, then,
2 cycles of the combination of etoposide, carboplatin
and ifosfamide), followed by the removal of the residual
retroperitoneal tumor and neck lymph nodes. After the
completion of therapy, lymph node swelling and lung
metastases were diminished. An FDG-PET/CT scan
that was performed 3 years after the completion of
therapy showed no abnormal findings (Figure 1b). Six
years after the completion of the therapy, mediastinal
and hilar node swelling was found on a CT scan (not
shown). He was therefore referred to our department
for an FDG-PET/CT study because recurrence was
suspected. Before therapy, the patient’s serum human
chorionic gonadotropin and α-fetoprotein levels were
65,800 mIU/mL (normal range < 5 mIU/mL) and
162.2 ng/mL (normal range < 20 ng/mL), respectively,
Figure 1 Case 1. A contrast-enhanced CT image taken at the time of the diagnosis of nonseminomatous malignant germ cell tumors with
multiple intrathoracic and abdominal lymph nodes and lung metastases (a) and maximum intensity projection (MIP) images of FDG-PET/CT scans
that were conducted 3 (b) and 6 years (c) after the completion of antineoplastic therapy and 8 (d) and 15 months (e) after the detection of
FDG-avid lesions. (a) CT images before antineoplastic therapy showing metastases in the bilateral hilar and mediastinal nodes and lungs with
pleural effusion. (b) No abnormal FDG uptake is observed. (c) Increased FDG uptake is evident in the bilateral hilar and mediastinal nodes
(maximum standardized uptake value (SUVmax) 17.7), abdominal nodes, and the left gluteal muscles. (d, e) A gradual decrease to normal is
observed concerning FDG uptake in these lesions.
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therapy.
The FDG-PET/CT scan showed multiple foci of ab-
normal uptake in the mediastinal and bilateral hilar
nodes, abdominal nodes such as the retrocrural and
para-aortic nodes, and left iliac artery nodes (Figure 1c).
Uptake in the left gluteal muscle was also noted.
Because of previous tumor involvement in the intratho-
racic nodes, a suspicion of tumor recurrence was
reported to the referring physicians. One cycle of
chemotherapy was administered. No change in the
lymph nodes swelling was noted on a CT scan, and
a subsequent FDG-PET/CT scan did not reveal a sig-
nificant change (not shown). Thus, a suspicion of
sarcoidosis or sarcoid reactions was reported, and
histological sampling from the mediastinal lymph nodes
by endobronchial ultrasound-guided transbronchial
needle aspiration confirmed noncaseating granulomas
without the evidence of a malignant tumor. Follow-up
was arranged thereafter to rule out recurrence. FDG-
PET/CT scans that were performed 8 and 15 months
after the detection of abnormal FDG uptake revealedgradual decrease in abnormal uptake (Figure 1d and e).
During the course of follow-up, the levels of serum
angiotensin converting enzyme (ACE) were normal.
Tumor recurrence has not been observed, and without
evidence of ocular, cardiac, lung, or skin sarcoid granu-
lomas, a diagnosis of sarcoid reactions was made.
Case 2
A 64-year-old woman underwent segmental resection of
the mandible for an osteosarcoma, which was followed
by chemotherapy (adriamycin) due to a positive margin.
On an FDG-PET/CT scan taken at the end of chemo-
therapy, only mild and nonspecific FDG uptake was ob-
served in the intrathoracic nodes (Figure 2a). Then, a
FDG-PET/CT scan that was performed 9 months after
therapy depicted high FDG uptake in the mediastinal
and bilateral hilar nodes (Figure 2b). Mediastinal node
biopsy revealed noncaseating granulomas with a negative
stain for acid-fast bacilli and fungi. Serum ACE levels
were assessed due to a suspicion of sarcoidosis, and were
found to be marginally elevated (26.1 U/L, normal range
7-25 U/L). Her serum ACE levels decreased to 20.7 U/L
Figure 2 Case 2. FDG-PET/CT images that were conducted 0 (a) and 9 months (b) after the completion of antineoplastic therapy for mandibular
osteosarcoma and 6 (c) and 28 months (d) after the detection of FDG-avid lesions.
Inoue et al. SpringerPlus 2013, 2:113 Page 4 of 7
http://www.springerplus.com/content/2/1/113two months after the PET/CT scan and remained
within a normal range for 2 years. Sarcoidosis was di-
agnosed on the basis of these findings, and the patient
was observed thereafter without treatment for sarcoid-
osis or malignancy. Follow-up PET/CT scans were
performed and they revealed decreases in FDG uptake
in the mediastinal and hilar nodes (Figure 2c and d).
Neither progression of sarcoidosis nor metastasis of
the osteosarcoma has been found.
Case 3
A 54-year-old woman presented with an oral floor
tumor. After being diagnosed with oral floor carcinoma,
she was treated with chemoradiotherapy (cisplatin, fluo-
rouracil, docetaxel, and a total of 70 Gy of radiation),
and then, due to the growth of the residual tumor,
total glossolaryngectomy with bilateral neck dissection
was performed.
An FDG-PET/CT scan that was conducted before
therapy showed high FDG uptake in the primary tumor,
as well as in the right neck node metastatic lesions,
without significant uptake in the intrathoracic nodesFigure 3 Case 3. MIP images of FDG-PET(/CT) scans that were obtained at
and 2 years (c) after the completion of antineoplastic therapy.(Figure 3a). Retrospectively, mild FDG uptake was noted
in the mediastinal and bilateral hilar nodes on a PET
scan that was performed 9 months after therapy
(Figure 3b). However, these findings were determined to
be due to non-specific reactive uptake. On an FDG-PET/CT
scan taken 2 years after therapy for restaging, moderate
FDG uptake was noted in the mediastinal and bilateral
hilar nodes, spleen, and right lung (Figure 3c). Histo-
logical sampling from the mediastinal node by
transbronchial lymph node biopsy confirmed the pres-
ence of noncaseating granulomas without evidence of
malignant tumor cells. Stains and cultures for acid-fast
bacilli and fungi were negative. Accordingly, a diagnosis
of sarcoidosis was made.
Case 4
A 54-year-old woman presented with a tumor in her left
breast. After being diagnosed with invasive ductal carcin-
oma, she underwent chemotherapy (cyclophosphamide,
epirubicin and fluorouracil) followed by mastectomy and
axillary lymph node dissection. At the time of diagnosis,
mediastinal and hilar lymphadenopathy was not observed.the time of the diagnosis of the malignancy (a) and 9 months (b)
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but intrathoracic lymph node swelling was subsequently
detected by a CT scan (not shown). She was referred to
our department for a FDG-PET/CT scan because recur-
rence was suspected.
On the FDG-PET/CT scan, there were multiple foci
of abnormal uptake in the bilateral supraclavicular
nodes, multiple mediastinal and bilateral hilar nodes,
and abdominal, iliac and bilateral inguinal nodes
(Figure 4). Due to the suspicion of malignant lymph-
oma, sarcoidosis, or metastases, an axillary node was
biopsied, and noncaseating granuloma was detected
without evidence of tumor recurrence. Stains and cul-
tures for acid-fast bacilli and fungi were negative. In
addition, increased levels of serum ACE were noted
(53.0 U/L). She was then diagnosed with sarcoidosis.
Another FDG-PET/CT scan that was performed 6 -
months after the diagnosis of sarcoidosis did not show
remarkable changes (not shown). Her serum ACE levels
decreased to 44.4 U/L 14 months after the diagnosis of
sarcoidosis, but they have not returned to normal after
2 years. She has been followed up for sarcoidosis, and
no recurrence of cancer has been observed.Figure 4 Case 4. Axial FDG-PET/CT images obtained 4 years after antineop
column, CT).Discussion
We identified 4 patients with sarcoid reaction (n=1) and
flare or new onset of sarcoidosis (n=3) who had been
treated for malignancy and exhibited FDG-avid lesions
on PET/CT scans. Abnormal uptake on FDG-PET/CT
was observed in the intrathoracic, abdominal, pelvic and
inguinal nodes and/or spleen and lung parenchyma, with
maximum standardized uptake value up to 17.7, 9 -
months to 6 years after antineoplastic therapy.
The present patients had different malignant tumors
and received different antineoplastic therapies; all pa-
tients received chemotherapy, albeit with different regi-
mens, with or without surgery and radiotherapy. As
observed in the present study, the new onset of previ-
ously undiagnosed sarcoidosis or the development of
sarcoid reactions has been observed in patients with di-
verse malignant neoplasms. This observation was more
common in patients with hematological malignancies,
such as malignant lymphoma (Suen et al., 1990;
Hunsaker et al., 1996; Goswami et al., 2010), but it was
also observed in patients with solid tumors, such as tes-
ticular cancer (Tjan-Heijnen et al., 1998; Karapetis et al.,
2001), breast cancer (Hunsaker et al., 1996; Hunt et al.,lastic therapy for left breast cancer (left column, FDG-PET; right
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2010; Umezu et al., 2010), head and neck cancer (Yao
et al., 2005), osteosarcoma (Okada et al., 2005) and
cancers of the digestive tract and genitourinary system
(Cohen and Kurzrock, 2007; Pavic et al., 2008;
Chowdhury et al., 2009). Antineoplastic treatment-
associated sarcoidosis has been commonly linked with
interferon-α and γ (Cohen and Kurzrock, 2007; Pavic
et al., 2008). The onset of sarcoidosis has, however, been
preceded by several other agents and combination
chemotherapy (Cohen and Kurzrock, 2007), as observed
in the present cases, and in cases that did not involve
antineoplastic chemotherapy (Suen et al., 1990; Hunt
et al., 2009). The type of preceding malignancy or anti-
neoplastic therapy, as well as the duration after the com-
pletion of therapy is, therefore, not sufficient for
distinguish a disseminated malignancy from sarcoidosis
or sarcoid reactions after antineoplastic therapy.
The relationship between malignancy and subsequent
sarcoidosis, as well as that between sarcoidosis and sub-
sequent malignancy, has been controversial (Cohen and
Kurzrock, 2007). In line with the notion that sarcoidosis
results from the exposure of genetically susceptible indi-
viduals to specific agents (American Thoracic Society,
1999), antineoplastic therapy may lead to the release of
antigens that can trigger the onset of sarcoidosis; how-
ever, the association might be fortuitous in some cases
(Brincker, 1995; Reich et al., 1995). Tumor-related sar-
coid reactions have also been considered to be caused by
soluble antigens that are derived from tumor cells
(Brincker, 1986). Sarcoidosis should be diagnosed by ex-
cluding the many diseases that are capable of producing
similar granulomas as well as tumor-related sarcoid re-
actions (American Thoracic Society, 1999). However, the
distinction between sarcoidosis occurring in an oncologic
patient and sarcoid reactions is difficult. The affected tis-
sues of sarcoid reactions are histologically identical to
granulomas in sarcoidosis, except that granulomas in sar-
coid reactions are B-cell positive whereas those in sarcoid-
osis are B-cell negative (Brincker and Pedersen, 1991).
The radiographical pattern of disease is not distinctive
between sarcoidosis and sarcoid reactions (Hunsaker
et al., 1996). Sarcoid reactions, however, can occur with
concomitant metastasis, although this is less frequent than
its occurrence without metastasis (Brincker, 1986). There-
fore, a recurrent tumor should be cautiously excluded in
cases in which the diagnosis of systemic sarcoidosis can-
not be confirmed.
FDG-PET(/CT) is a useful technique both in managing
a malignancy and assessing the extent of the organ in-
volvement of sarcoidosis (Teirstein et al., 2007; Braun
et al., 2008). Regarding the differential diagnosis of dis-
seminated malignancies from sarcoidosis or sarcoid reac-
tions, symmetrical hilar FDG uptake may be related to abenign cause (Karam et al., 2008). It is however difficult
to apply this finding to patients with previous thoracic
node involvement of malignancies such as the present
Case 1. In addition, the characteristics of hilar FDG up-
take in patients with granulomatous disease can be simi-
lar to those in patients with metastatic disease (Karam
et al., 2008). Additionally, the differential diagnosis for
newly developed multiple FDG-avid lesions in lymph
nodes, spleen, and lung parenchyma as found in the
present study would overlap those of sarcoidosis includ-
ing malignant lymphoma, infectious diseases such
as mycobacteriosis and mycosis, and lymphadenitis
(American Thoracic Society, 1999). Therefore, the utility
of FDG-PET(/CT) is in pinpointing the organs that are
candidates for diagnostic biopsy and not distinguishing
between the disseminated malignancy and granuloma-
tous and inflammatory diseases. In addition, any clinical
data, such as the levels of tumor markers as in the
present Case 1, should be utilized in reporting FDG-PET
findings, if available, to suggest a differential diagnosis
other than metastatic malignancy for FDG-avid lesions
to referring physicians.
In the present study, gradual decreases in FDG uptake
were observed during follow-up after the detection of
FDG-avid lesions in 2 patients. Nearly two-thirds of pa-
tients with sarcoidosis have a spontaneous remission
(American Thoracic Society, 1999; Iannuzzi et al., 2007).
More importantly, the decrease in FDG uptake could be
a marker to rule out recurrent malignancy in oncologic
patient who have neither histopathological proof of me-
tastasis of malignancy nor fulfill the criteria for systemic
sarcoidosis as in the present Case 1. However, the long
duration to confirm a remarkable decrease in FDG up-
take is a disadvantage, and even 6 months would not be
sufficient for judging relevant changes in FDG uptake, as
observed in the present Case 4. To overcome this disad-
vantage, FDG-PET(/CT) could be used to assess early
metabolic responses to corticosteroid therapy to dis-
criminate sarcoidosis and sarcoid reactions from malig-
nancy in some cases (Aide et al., 2009). Conversely, the
spontaneous remission of sarcoidosis or sarcoid reac-
tions could mimic the regression of the malignancy if
antineoplastic therapy is performed on the basis of a
misdiagnosis of malignancy and sarcoidosis. PET using
F-18-alpha-methyltyrosine could be used to distinguish
sarcoidosis from malignancy, although malignancy
would not be excluded if the findings were negative
(Kaira et al., 2007).
In the present study, only patients who displayed ab-
normal increases in FDG uptake in the intrathoracic
nodes were selected as possible cases of sarcoidosis or
sarcoid reactions on the basis of preceding reports
(Hunsaker et al., 1996; Chowdhury et al., 2009; Hunt
et al., 2009). In a few reports, however, sarcoid reactions
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the spleen (Reilly et al., 2007), or axial lymph nodes
(Martella et al., 2012). Therefore, our study may have
failed to include cases of sarcoidosis or sarcoid reactions
that occurred in organs other than intrathoracic nodes.
In future investigations, we should attempt to distin-
guish sarcoid reactions from malignancy when we ob-
serve the development of FDG-avid lesions without the
involvement of the intrathoracic nodes.
In conclusion, the present study demonstrated that the
occurrence of a sarcoidosis or sarcoid reaction was ob-
served in patients with several types of solid malignant
tumors with variable durations since the end of theraphy
and with variable types of antineoplastic therapy. FDG-
avid lesions due to sarcoidosis or sarcoid reactions could
mimic the recurrence of malignancy in oncologic pa-
tients. Symmetrical FDG uptake in the hilar and/or me-
diastinal nodes is a typical finding of sarcoidosis and
sarcoid reactions on FDG-PET(/CT). Therefore, these
conditions should not be discounted even in patients
with malignancies that previously involved the intratho-
racic nodes.
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